|Articles|June 15, 2002
- BioPharm International-06-01-2002
- Volume 15
- Issue 6
Finding Funding in Biotechnology: Keeping the Companies Alive
Author(s)Mark D. Dibner, Michael Howell
by Mark D. Dibner, BioAbility, LLC, and Michael Howell Biotechnology appears to be "the place to be" for venture capitalists, capturing the largest percentage increase in investment for 2001. The value of biotech companies has risen sharply, and many economists are predicing an end to the IPO drought.
Advertisement
Articles in this issue
over 23 years ago
Negotiating and Structuring Strategic Alliancesover 23 years ago
Stem Cells and Xenotransplantation: Ethics, Patents, and Politicsover 23 years ago
Unlocking the Value of R&D: Managing the Risksover 23 years ago
Viewpoint: United Kingdom highlights biomanufacturing capabilitiesover 23 years ago
Inside Washington: Safety, Risk, and Biotechnology Regulationover 23 years ago
Criminal Penalties for Theft of Biological MaterialNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Distribution Resilience: Meeting Global Demand and Delivering Faster, More Reliable Service
2
Top 10 Questions from CPHI Frankfurt: Building Pharma Resilience a Common Theme
3
In-Vivo Cell Therapy Model Aims to Reduce Manufacturing Challenges
4
Streamlining Procurement and Inventory Management Leads to Increased Productivity
5
